81.   The JAMA study noted that new drugs are heavily marketed to both doctors and consumers, which means they may be in wide distribution before adverse effects are known.

82.   The PDR is often out of date because it is published annually and often uses data gathered before a drug was marketed rather than updated information.

83.   The most important incentive is the exclusive right to market the drug for seven years.

84.   The pharmaceutical concern would manufacture and market the drug.

85.   The two companies jointly market the drug, also known as fluvoxamine, which is already approved for adults.

86.   The two will jointly market the drug, launching it in the U.S. before the end of the year.

87.   Then, it must get clearance from the FDA to market the drug.

88.   Those issues are being negotiated between the agency and Danco Laboratories, the group that seeks to market the drug.

89.   Upjohn is asking to market the drug as Rogaine Extra Strength for Men.

90.   When Amgen got the patent, Genzyme was forced to abandon its own research and is prohibited from marketing the drug on its own.